Journal: bioRxiv

Article Title: Symmetric Dimethylarginine Modification Drives Shared and Divergent Antigen Reactivity in Lupus

doi: 10.64898/2026.09.22.753525

Figure Lengend Snippet: (A) Sera from MRL lpr mice (n=12, bled weekly from 8 to 13 weeks of age) were analyzed by ELISA using synthetic 10×RG peptides: native sequence (GRGRGRGRGRGRGRGRGRGR) vs. SDMA-modified (lowercase ‘r’ denotes SDMA; GrGrGrGRGRGrGrGrGRGR). All 12 mice developed anti SDMA antibody titers above the corresponding native controls, and the majority (9/12) showed a gradual increase in anti-SDMA titers over time. (B) Immunoblotting of HEp-2 lysates revealed progressive changes in band patterns from 10 weeks onward. To identify SDMA specific reactive proteins, cells were pretreated with the methyltransferase inhibitor EPZ015666 (EPZ) before lysis. A prominent ∼15 kDa band (arrowhead) was markedly reduced by EPZ pretreatment, supporting its recognition by anti SDMA antibodies. (C) Sera from three 12 week old MRL lpr littermates (Lpr 1, 2, 3) each showed distinct band patterns against the cell lysates. EPZ pretreatment of the cells reduced the intensity of several bands in all three mice. (D) Workflow for isolating hybridoma clones from individual plasma cells to obtain monoclonal antibodies (mAbs) specific for SDMA. MRL lpr mice were not immunized with any antigen; thus, the resulting mAbs represent naturally arising autoantibodies. (E) Two antibody clones were tested against the native versus SDMA peptide array shown in Figurè3. Clone P4A2F4 reacted extensively with most SDMA containing peptides, whereas clone P2C1C10 showed no reactivity. (F) The two mAbs produced different band patterns on cell lysates. P4A2F4 recognized bands that were reduced in EPZ pretreated lysates, consistent with SDMA specificity. (G) After implantation of the SDMA-reactive hybridoma clone into the peritoneal cavity of healthy BALB/c mice, the kidneys showed extensive IgG deposition, reminiscent of human lupus nephritis.

Article Snippet: High-binding ELISA plates (Greiner Bio-One, 655081) were coated with 250 ng/well of streptavidin (Leinco Technologies, S203) overnight at 4°C.

Techniques: Enzyme-linked Immunosorbent Assay, Sequencing, Modification, Western Blot, Lysis, Clone Assay, Clinical Proteomics, Bioprocessing, Autoantibodies, Peptide Microarray, Produced

Journal: Toxicology Reports

Article Title: Presence of glyphosate in endometrial cancer tissue: A cross-sectional study

doi: 10.1016/j.toxrep.2026.102255

Figure Lengend Snippet: Glyphosate level in serum in study groups (mean±SEM). ECLH: Low-grade and High-grade endometrial cancer (n = 32); ECL: Low-grade endometrial cancer (n = 22); EIN: Endometrial intraepithelial neoplasia (n = 4) and C: control (n = 32). Glyphosateconcentration concentration in serum, measured in ECLH, ECL, EIN and C groups. *ECLH serum level significantly differs from control serum level; GLY serum: ECLH serum 0.1829 ± 0.0272 ng/ml; ECL serum 0.2148 ± 0.0406 ng/ml; EIN serum 0.1938 ± 0.00488 ng/ml and C serum 0.1297 ± 0.0167 ng/ml.

Article Snippet: A commercial kit (ABRAXIS Glyphosate Plate ELISA Kit, PN 500205, Gold Standard Diagnostics, Warminster, US) was used in this study.

Techniques: Control, Concentration Assay

Journal: Toxicology Reports

Article Title: Presence of glyphosate in endometrial cancer tissue: A cross-sectional study

doi: 10.1016/j.toxrep.2026.102255

Figure Lengend Snippet: Glyphosate level in endometrial tissue in study groups (mean±SEM). ECLH: Low-grade and High-grade endometrial cancer (n = 32); ECL: Low-grade endometrial cancer (n = 22); EIN: Endometrial intraepithelial neoplasia (n = 4) and C: control (n = 32). GlyphosateconcentrationGLY concentration in endometrial tissue, measured in ECLH, ECL, EIN and C groups. We adjusted the mean concentration values for the endometrium by applying a serum density value of 1.025 g/ml as a conversion factor: from pg/ml to pg/g and ng/ml to ng/g. *ECLH endometrium level shows a significant difference from the control serum level; GLY endometrium: ECLH endometrium 0.4174 ± 0.3461 ng/g; ECL endometrium 0.4073 ± 0.04162 ng/g; EIN endometrium 0.3798 ± 0.09556 ng/g and C endometrium 0.318 ± 0.0251 ng/g.

Article Snippet: A commercial kit (ABRAXIS Glyphosate Plate ELISA Kit, PN 500205, Gold Standard Diagnostics, Warminster, US) was used in this study.

Techniques: Control, Concentration Assay

Journal: Toxicology Reports

Article Title: Presence of glyphosate in endometrial cancer tissue: A cross-sectional study

doi: 10.1016/j.toxrep.2026.102255

Figure Lengend Snippet: Glyphosate level in serum and endometrial tissue in study groups (mean±SEM). ECLH: Low-grade and High-grade endometrial cancer (n = 32); ECL: Low-grade endometrial cancer (n = 22); and C: control (n = 32). Glyphosateconcentration concentration in endometrial tissue, measured in ECLH, ECL, and C groups. We converted concentration mean values in the case of endometriumendometrium using 1025 g/ml serum density value as a multiplier: pg/ml to pg/g, ng/ml to ng/g. *Endometrium level significantly differs from control serum level in all study groups. P < 0.0001; GLY levels: ECLH serum 0.1829 ± 0.0272 ng/ml; endometrium 0.4174 ± 0.3461 ng/g; ECL serum 0.2148 ± 0.0406 ng/ml; endometrium 0.4073 ± 0.04162 ng/g; and C serum 0.1297 ± 0.0167 ng/ml; endometrium 0.318 ± 0.0251 ng/g.

Article Snippet: A commercial kit (ABRAXIS Glyphosate Plate ELISA Kit, PN 500205, Gold Standard Diagnostics, Warminster, US) was used in this study.

Techniques: Control, Concentration Assay